BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18771701)

  • 1. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.
    Choi YS; Hoory T; Monie A; Wu A; Connolly D; Hung CF
    Vaccine; 2008 Oct; 26(46):5855-63. PubMed ID: 18771701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
    Mattarollo SR; Steegh K; Li M; Duret H; Foong Ngiow S; Smyth MJ
    Immunol Cell Biol; 2013 Jan; 91(1):105-14. PubMed ID: 23090488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
    Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
    J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
    Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
    Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70.
    Chang CL; Tsai YC; He L; Wu TC; Hung CF
    Cancer Res; 2007 Oct; 67(20):10047-57. PubMed ID: 17942939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.
    Gonzalez-Aseguinolaza G; Van Kaer L; Bergmann CC; Wilson JM; Schmieg J; Kronenberg M; Nakayama T; Taniguchi M; Koezuka Y; Tsuji M
    J Exp Med; 2002 Mar; 195(5):617-24. PubMed ID: 11877484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.
    Kim D; Hung CF; Wu TC; Park YM
    Vaccine; 2010 Oct; 28(45):7297-305. PubMed ID: 20817010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
    Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ
    Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
    Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
    J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression.
    Neumann S; Young K; Compton B; Anderson R; Painter G; Hook S
    Vaccine; 2015 Oct; 33(43):5838-5844. PubMed ID: 26363382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide.
    Nakagawa R; Inui T; Nagafune I; Tazunoki Y; Motoki K; Yamauchi A; Hirashima M; Habu Y; Nakashima H; Seki S
    J Immunol; 2004 Jun; 172(11):6550-7. PubMed ID: 15153469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma.
    Nishihori Y; Kato K; Tanaka M; Okamoto T; Hagiwara S; Araki N; Kogawa K; Kuribayashi K; Nakamura K; Niitsu Y
    Cancer Biol Ther; 2009 Sep; 8(18):1763-70. PubMed ID: 19901518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
    Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection.
    Reilly EC; Thompson EA; Aspeslagh S; Wands JR; Elewaut D; Brossay L
    PLoS One; 2012; 7(5):e37991. PubMed ID: 22649570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
    Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
    J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
    Okazaki S; Iwasaki T; Yuba E; Watarai S
    J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-peritoneal hyperthermia combining α-galactosylceramide in the treatment of ovarian cancer.
    Wu CC; Chuang YT; Hsu YT; Huang JT; Wu TC; Hung CF; Yang YC; Chang CL
    PLoS One; 2013; 8(7):e69336. PubMed ID: 23935988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.